Molecular Detection (MDI) and Palex Medical, one of Spain's distributors of medical device and diagnostic products to hospitals, have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay, an in-vitro diagnostic test in Spain.
Palex had recently launched Detect-Ready MRSA assay into the Spanish market. MDI claimed that with the Detect-Ready MRSA assay, healthcare providers would benefit with enhanced accuracy, speed, flexibility and cost-effectiveness.
According to MDI the technology in the Detect-Ready kits provides a differential diagnosis engine that produces accurate results, minimising the false positives and false negatives experienced with other MRSA screening kits.
The Detect-Ready MRSA kit is a qualitative real-time PCR (rt-PCR) assay for the direct detection of MRSA nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.
Detect-Ready kits are off-the-shelf room temperature-stabilised and require no refrigeration like other test kits which require special handling. The kits are compatible with multiple rt-PCR platforms currently found in clinical laboratories, including the Roche LightCycler, Qiagen Rotor-Gene and Cepheid SmartCycler.
The Detect-Ready MRSA assay kit has received CE mark certification for sale in the EU. The Detect-Ready MRSA assay is also available in Germany, the UK, Ireland, Switzerland and Austria.
Todd Wallach, CEO of MDI, said: “Our Detect-Ready MRSA assay offers important advantages to the growing market for MRSA screening, and we are pleased to partner with Palex Medical for distribution to the important Spanish market.”
Josep Maria Espinalt, general manager of Palex Medical, said: “Spain is introducing proactive control programs to combat the major problem that MRSA infections pose to health facilities worldwide, and we believe that the combination of accuracy, speed, versatility and cost-effectiveness of the Detect-Ready MRSA assay will contribute to the success of these efforts.
“Our dedicated team of highly skilled professionals is committed to bringing our expertise and infrastructure to help ensure the clinical and commercial success of the Detect-Ready MRSA assay in Spain.”